Sequential treatment of metastatic renal cancer in a complex evolving landscape

Affiliations

¹ Clinical Department, Faculty of Biomedical Sciences, European University of Madrid, Getafe, Madrid, Spain.
² Molecular Oncology, Biodonostia Research Institute, San Sebastián, Spain.
³ Department of Pathology, Cruces University Hospital, Biocruces-Bizkaia Research Institute, University of the Basque Country (UPV/EHU), Leioa, Barakaldo, Spain.

Editorial

Javier C Angulo et al. Ann Transl Med. 2019 Dec.

. 2019 Dec;7(Suppl 8):S272.

doi: 10.21037/atm.2019.12.05.

¹ Clinical Department, Faculty of Biomedical Sciences, European University of Madrid, Getafe, Madrid, Spain.
² Molecular Oncology, Biodonostia Research Institute, San Sebastián, Spain.
³ Department of Pathology, Cruces University Hospital, Biocruces-Bizkaia Research Institute, University of the Basque Country (UPV/EHU), Leioa, Barakaldo, Spain.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Long survival of patients with metastatic clear cell renal cell carcinoma. Results of real life study of 344 patients.
Voog E, Campillo-Gimenez B, Elkouri C, Priou F, Rolland F, Laguerre B, Elhannani C, Merrer J, Pfister C, Sevin E, L'Haridon T, Hasbini A, Moise L, Le Rol A, Malhaire JP, Delva R, Vauléon E, Cojocarasu O, Deguiral P, Cumin I, Cheneau C, Schlürmann F, Delecroix V, Boughalem E, Mollon D, Ligeza-Poisson C, Abadie-Lacourtoisie S, Monpetit E, Chatellier T, Desclos H, Coquan E, Joly F, Tessereau JY, Dupuy S, Déniel Lagadec D, Marhuenda F, Grudé F. Voog E, et al. Int J Cancer. 2020 Mar 15;146(6):1643-1651. doi: 10.1002/ijc.32578. Epub 2019 Aug 1. Int J Cancer. 2020. PMID: 31318983

1. Voog E, Campillo-Gimenez B, Elkouri C, et al. Long survival of patients with metastatic clear cell renal cell carcinoma. Results of real life study of 344 patients. Int J Cancer 2019. [Epub ahead of print]. 10.1002/ijc.32578 - DOI - PubMed
1. Kadono Y, Konaka H, Izumi K, et al. Efficacy and safety of cytokines versus first-line sunitinib and second-line axitinib for patients with metastatic renal cell carcinoma (ESCAPE study): A study protocol for phase III randomized sequential open-label study. Contemp Clin Trials Commun 2019;15:100403. 10.1016/j.conctc.2019.100403 - DOI - PMC - PubMed
1. Rossetti S, D'Aniello C, Iovane G, et al. Sequential treatment with pazopanib and everolimus in metastatic renal cell carcinoma. Front Pharmacol 2017;8:484. 10.3389/fphar.2017.00484 - DOI - PMC - PubMed
1. Munárriz J, Reynés G, Sánchez-Lorenzo L, et al. Sunitinib rechallenge in advanced renal cell carcinoma: outcomes of a multicenter retrospective study. Cancer Chemother Pharmacol 2019;84:781-9. 10.1007/s00280-019-03913-3 - DOI - PubMed
1. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018;378:1277-90. 10.1056/NEJMoa1712126 - DOI - PMC - PubMed